Huntington’s disease is different from many conditions in this series because its central genetic cause is known: an expanded CAG repeat in the HTT gene. The inherited repeat length is strongly related to disease risk and, statistically, to age at onset.
That makes identical twins a particularly revealing test. They can carry the same pathogenic expansion and the same measured CAG length — yet still differ in when symptoms begin and how the disease presents.
Quick answer
If the Huntington mutation is causal, how can identical twins differ?
A causal mutation can be necessary without determining every feature of disease. Inherited CAG length is central, but somatic repeat expansion, DNA-repair modifiers, postzygotic biological changes and other factors can influence when and how Huntington disease becomes clinically visible.
Key takeaways
- An identical twin pair with 39 CAG repeats differed by at least seven years in clinical Huntington onset.
- Another identical pair with the same Huntington mutation differed in onset and in motor, behavioural and psychiatric presentation.
- A twin case cannot prove that smoking, toxin exposure or another observed difference caused the discordance.
- Modern genetic studies show that DNA-repair pathways and somatic expansion of the HTT CAG repeat help modify age at onset and disease trajectory.
- Huntington illustrates a crucial distinction: knowing the central genetic cause is not the same as knowing the exact timing or phenotype.
A disease with a known central genetic cause
Huntington disease is caused by an expanded CAG repeat in HTT. At higher repeat lengths, penetrance is high, and repeat length contributes strongly to the expected timing of disease. This is far more direct than the polygenic risk architecture of common Alzheimer or Parkinson disease.
But even here, genetic causation is not an exact personal timetable. People with the same inherited repeat length can differ in age at onset and progression.
The identical twins who differed by at least seven years
A 2005 report described 71-year-old monozygotic twin sisters who both had 39 CAG repeats. One had developed clinical Huntington disease at least seven years before her genetically confirmed co-twin, who was still neurologically healthy at the later examination.
The authors noted differences including cigarette use and industrial toxin exposure as possible explanations. Those observations are hypotheses from one pair — not evidence that smoking or toxins caused the timing difference.
Same mutation, different symptoms
A separate report described 46-year-old monozygotic twin men carrying the same Huntington mutation. One developed chorea, dysarthria and depressed mood from age 32; the other presented around age 35 with gait disturbance and later showed a more rigid, hypokinetic motor pattern alongside aggressive and obsessive behaviour.
The authors suggested postzygotic events as a likely contributor. The case illustrates expressivity: the same causal genetic background can produce different combinations and timing of symptoms.
Modern genetics explains part of the missing variation
Genome-wide modifier studies have transformed the Huntington story. Several important modifiers involve DNA mismatch-repair pathways, and somatic expansion means the inherited CAG repeat can continue to expand in some cells and tissues during life.
A major 2025 Nature Genetics study linked mismatch-repair-related genes such as MSH3, PMS2 and FAN1 to somatic expansion and clinical phenotypes, while also identifying modifiers that affect cognition or motor function through other pathways. The inherited HTT expansion remains causal; these factors help explain variation around it.
Penetrance and expressivity are different questions
Penetrance asks whether a genetic variant leads to a detectable phenotype. Expressivity asks how that phenotype appears — including timing, symptom mix and severity. Huntington disease makes the distinction unusually easy to see.
Even when the central mutation is highly penetrant, modifiers can affect the clinical path. Identical twins help reveal those modifiers because so much of the starting genome is matched.
TwinPare perspective: cause is not the same as a complete script
Huntington is perhaps the clearest demonstration in this series that biology can be genetically caused and still biologically variable. The mutation tells us something fundamental. It does not specify every future event in every cell.
Twin research therefore remains valuable even when the causal gene is already known. It can shift the question from “what causes the disease?” to “what modifies the effect of the cause?”
Source notes
The sources have been verified and editorially reviewed for this article. The limitations below show which level of conclusion the sources support.
- [friedman-2005] Monozygotic Twins Discordant for Huntington Disease After 7 Years Joseph H Friedman et al.. Archives of Neurology, 2005. Evidence type: Case report of genetically confirmed monozygotic twin sisters with the same HTT CAG repeat length Limitation: One twin with 39 CAG repeats had developed Huntington disease while her genetically confirmed identical co-twin with the same repeat count remained neurologically healthy at least seven years later. Differences in smoking and industrial exposures were hypotheses, not proven explanations. PubMed DOI
- [anca-2004] Different phenotypic expression in monozygotic twins with Huntington disease M H Anca et al.. American Journal of Medical Genetics Part A, 2004. Evidence type: Case report of monozygotic twin men with the same Huntington disease mutation Limitation: The twins differed in age at onset and in motor, behavioural and psychiatric features. The authors proposed postzygotic events as a likely explanation for phenotypic differences. PubMed DOI
- [gemhd-2025] Genetic modifiers of somatic expansion and clinical phenotypes in Huntington’s disease highlight shared and tissue-specific effects Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Nature Genetics, 2025. Evidence type: Genome-wide genetic modifier analysis of somatic HTT repeat expansion and Huntington clinical phenotypes Limitation: Supports a modern model in which mismatch-repair-related genes, somatic CAG expansion and additional modifiers influence clinical timing and progression beyond inherited CAG length alone. PubMed PMC DOI
- [hd-somatic-2026] Huntington disease: somatic expansion, pathobiology and therapeutics Review authors indexed in PubMed. Review article, 2026. Evidence type: Contemporary review of somatic CAG expansion and genetic modifiers in Huntington disease Limitation: Reviews evidence that DNA-repair genes and somatic CAG expansion in affected tissues help modify disease onset and progression. This mechanism complements, rather than replaces, the central causal role of the inherited HTT expansion. PubMed
Editorial source review
This section shows how the article's key factual claims are linked to the source.
Phrasings that require caution
- Huntington disease is a serious inherited neurological disorder; genetic testing and counselling require appropriate clinical support.
- Do not infer causal effects from lifestyle differences observed in a single twin pair.
- Somatic expansion and genetic modifiers explain part of disease variation but do not diminish the central causal role of the inherited HTT expansion.
| ID | Claim | Source support | Caution |
|---|